Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem
23.10.2026 13:12:00 CEST | Business Wire | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/
Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon.
Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environmental accountability where Elevate joining our ecosystem integrates highly disruptive, resource-saving agricultural technology with our environmental strategy to mitigate industrial carbon building hyper-efficient infrastructure at scale to protect natural ecosystems."
Amin Jadavji, Elevate Farm CEO added "Our mission has always been to build a sustainable, scalable agricultural baseline using less land and water than ever thought imaginable and partnering Digital Reef creates a direct nexus between the computational demands of tomorrow and the foundational resource requirements of our planet facilitating digital expansion complimented with an automated near-zero-waste food supply model."
As part of the Reef Origin impact fund Xange.com are appointed to ensure data transparency employing digital Measurement, Reporting, and Verification (dMRV) protocols including energy and water consumption, carbon offsets and environmental assets produced by Elevate Farms’ - ensuring completely verifiable carbon and conservation accounting. Employing IoT technology at Elevate’s latest facility in the UAE the alliance between Elevate Farm, Digital Reef and Xange.com is, supported by several UAE universities, promoting food sovereignty globally alongside high level efficiency of land, water, energy and fertiliser resources.
About Elevate Farms
Elevate Farms Inc. (www.elevate.farm) is a technology-driven vertical farming company committed to mitigating the climate realities of traditional agriculture. Utilizing proprietary automation, advanced photobiology, and ultra-precise climate controls, Elevate Farms produces high-density, nutrient-rich crops at a fraction of the environmental cost—saving substantial volumes of fresh water, minimizing land use, and eliminating chemical runoff from the global food chain.
About Digital Reef
Digital Reef (www.digital-reef.io), the digital infrastructure business of London, UK based Reef Origin is developing a global 3.3GW data centre pipeline delivering ecosystems co-locating sustainable digital, clean energy, food, water, industry, community and ecology infrastructure delivered against the United Nations Sustainable Development Goals.
About Reef Origin
Reef Origin (www.reeforigin.com) is a sustainability focused global real estate, infrastructure and technology developer and investor with a pipeline of projects of $40B+ in enterprise value.
About Xange.com
Xange.com International Holding S.à r.l. (www.xange.com) is a Luxembourg-based environmental intelligence software and market infrastructure company, serving governments and enterprises with digital MRV systems, market infrastructure solutions, sustainability reporting, and Article 6-aligned environmental market participation.
Forward-looking statements
This press release contains forward-looking statements, including statements about project pipelines and the expected environmental outcomes of the agreement. These statements reflect current expectations and are subject to risks and uncertainties, including regulatory approvals, market conditions and project delivery. Actual results may differ materially. This press release is for information only and does not constitute an offer or invitation to invest.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261022393352/en/
Contacts
Media Contact
Jude Slater, Reef Origin
Email: jslater@reeforigin.com
Tel: +44 7960 345003
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press Release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press Release
Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets.8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Relfydess is the first and only ready-to-use liquid neuromodulator developed with PEARL Technology, designed to deliver a highly active, innovative, complex-free molecule that addresses the real needs of patients and healthcare professionals.1,2,4,5 It is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.1,10 At a time whenpatients and healthcare professionals are increasingly seeking high-performance neuromodulators that rapidly deliver long-lasting, natural-looking outcomes, Re
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press Release
Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoint, demonstrating non-inferiority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom